About Actavis + Forest
On July 1, 2014, Actavis (NYSE:ACT) completed the acquisition of Forest Laboratories,
creating one of the world’s fastest-growing specialty pharmaceutical companies with
annual revenues of more than $15 billion anticipated for 2015. The combination creates
a Company with size and scale, a balanced offering of strong brands and generics, a focus
on strategic, lower-risk drug development and a generic DNA, focused on cost efficiency
across the expanded organization.
Join one of the world’s fastest-growing specialty pharmaceutical companies.
The combination of Actavis + Forest is creating exciting career opportunities
across our now larger and stronger global company. As we continue integrating
our recruiting processes and systems, you may view career opportunities at the
Actavis career sites.